Blenrep
Blenrep ingredients
| Active ingredient | Strength |
|---|---|
| Belantamab Mafodotin | 50 mg/mL |
What Blenrep is used for
The FDA lists the approved uses on the official label (below). In the EU, belantamab mafodotin is approved as Blenrep for:
Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Blenrep
- Generic name
- Belantamab mafodotin
- Made by
- GlaxoSmithKline LLC
- Forms
- Injection, Powder, For Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761440
- On the US market since
- 2025
Official information
- MedlinePlus drug information (search for Belantamab mafodotin)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Blenrep?
Blenrep (Belantamab mafodotin) is a cancer medicine made by GlaxoSmithKline LLC, approved by the US FDA.
What are the ingredients of Blenrep?
Blenrep contains Belantamab Mafodotin (50 mg/mL).
Is Blenrep approved in Europe?
The same active substance is approved in the EU as Blenrep.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA